ClinicalTrials.gg
Status unknownNCT02013102DREAMUpdated Dec 17, 2013

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome

A Phase 4 interventional study of Decitabine Injection in Myelodysplastic Syndrome, sponsored by Cttq. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-17.

Sponsored by Cttq (part of Sino Biopharmaceutical Limited) · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.

Planned enrollment
3rd of 74
240 · median 43
Started
2013
with 4 others
Phase 4
3 of 75
none open now
Registered
44th of 75
by date

Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 3rd largest by planned enrollment of the 74 interventional ones that give a count, is one of 5 that started in 2013, is one of 3 in phase 4, and was the 44th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing decitabine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate of the safety and efficacy of decitabine treatment of Myelodysplastic Syndrome.

Read the detailed description

Total subjects: 240, doseⅠgroup of 120 patients, doseⅡgroup of 120 patients. Subjects are stratified randomize. If necessary, participants accepted best supportive therapy.

03

Conditions studied

  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18;
  • The diagnosis of MDS patients comply WHO2008 standards;
  • IPSS score≥0.5;
  • WHO classification for patients RCUD, RARS and transfusion-dependent RCMD;
  • PS score: 0-2;
  • Expected survival≥3 months;
  • Serum ≤1.5*, serum and AST≤2.5*ULN, serum Cr≤1.5*ULN;
  • Subjects signed form in line with GCP requirements.

Exclusion criteria

Exclusion Criteria:

  • Can not marrow ;
  • Previously diagnosed AML;
  • Received azacitidine or decitabine treatment any time before;
  • Being diagnosed with other in the prior 12 months;
  • Pregnant or lactating women;
  • Failure to control systemic fungal, bacterial or viral infection;
  • Known or suspected allergy to decitabine;
  • Known (HIV) or or C classes of active viral infection;
  • Have a history of neurological or psychiatric disorders, including epilepsy or dementia;
  • 3 or 4 degree peripheral neuropathy;
  • According to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the patients completed the study in patients;
  • Using other experimental drugs or participating in other clinical trials in the prior one months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Arm Ⅰ

    Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks.

    Drug: Decitabine Injection

  • Experimental
    Arm Ⅱ

    Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.

    Drug: Decitabine Injection

Interventions

  • Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.

    Also known as: qingweike

06

What researchers measure

Primary outcomes

  1. The safety and efficacy of decitabine treatment of Myelodysplastic Syndrome.

    The primary efficacy evaluation: ORR The secondary efficacy evaluation: CR,mCR,PR,HI, PFS in one year, Cytogenetic response, transfusion requirements, et al.

    Time frame: 2-4 months

07

Study locations

1 of 1 sites recruiting
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
    Recruiting
    • LIU HUI, MD · Contact
    • Shao Zonghong, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2013
First posted
Dec 17, 2013
Start
Mar 2013
Primary completionEst.
Dec 2015
CompletionEst.
Dec 2015
Last update
Dec 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02013102
Lead sponsor
Cttq
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Mar 2013
Primary completion
Dec 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Dec 17, 2013

Study contacts

Liu Hui, MD
Contact
0086-022-60362636
Shao Zonghong, MD
principal investigator · Tianjin Medical University General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion